• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

瑞德西韦-COVID-19:牙科中的药物相互作用。

Remdesivir-COVID-19: drug interactions in dentistry.

机构信息

Department of Medically Compromised Patients in Dentistry, School of Dentistry, University of Granada, Granada, Spain.

出版信息

Eur Rev Med Pharmacol Sci. 2020 Sep;24(18):9739-9743. doi: 10.26355/eurrev_202009_23065.

DOI:10.26355/eurrev_202009_23065
PMID:33015819
Abstract

OBJECTIVE

Remdesivir is a nucleotide analogue prodrug that inhibits viral RNA polymerases. It has been recognized recently as a promising antiviral drug against a wide array of RNA viruses (including SARS/MERS-CoV5). We aimed at determining which drugs used in dentistry interact with Remdesivir in order to avoid adverse reactions that may worsen the condition of patients with COVID-19.

MATERIALS AND METHODS

A literature review was conducted to identify potential drug interactions between remdesivir (used in the treatment of COVID-19) and drugs prescribed in dentistry. The search was made in the databases PubMed and MEDLINE and official websites using key terms remdesivir, drug interactions and dentistry for articles published up to 31st July 2020.

RESULTS

According to the articles reviewed, a total of 279 drugs interact with Remdesivir. Two major interactions have been reported, 277 moderate drug interactions, and one with alcohol/food. The drug interactions involving drugs prescribed in dentistry are all moderate drug interactions and are (according to drug group): (1) antibiotics: azithromycin, clavulanate, doxycycline, erythromycin, levofloxacin; (2) antifungals: clotrimazole, fluconazole, itraconazole, ketoconazole; (3) non-steroidal anti-inflammatories (NAIDS): celecoxib diclofenac, etodolac, flurbiprofen, ibuprofen, ketoprofen, ketorolac, mefenamic acid, naproxen, piroxicam.

CONCLUSIONS

It is clinically necessary for oral health professionals to be aware of possible drug interactions that may occur between remdesivir and drugs commonly prescribed in dentistry in order to prevent adverse reactions that may even endanger the life of a patient with COVID-19.

摘要

目的

瑞德西韦是一种核苷酸类似物前药,可抑制病毒 RNA 聚合酶。最近,人们发现它是一种针对多种 RNA 病毒(包括 SARS/MERS-CoV5)的有前途的抗病毒药物。我们旨在确定牙科中使用的哪些药物与瑞德西韦相互作用,以避免可能使 COVID-19 患者病情恶化的不良反应。

材料和方法

对瑞德西韦(用于治疗 COVID-19)与牙科处方药物之间潜在药物相互作用的文献进行了综述。使用关键词 remdesivir、drug interactions 和 dentistry 在 PubMed 和 MEDLINE 数据库以及官方网站上进行了搜索,检索截止日期为 2020 年 7 月 31 日。

结果

根据综述的文章,共有 279 种药物与瑞德西韦相互作用。报告了两种主要相互作用,277 种中度药物相互作用,一种与酒精/食物相互作用。涉及牙科处方药物的药物相互作用均为中度药物相互作用,分别为:(1)抗生素:阿奇霉素、克拉维酸、多西环素、红霉素、左氧氟沙星;(2)抗真菌药:克霉唑、氟康唑、伊曲康唑、酮康唑;(3)非甾体抗炎药(NAIDS):塞来昔布、双氯芬酸、依托度酸、氟比洛芬、布洛芬、酮洛芬、酮咯酸、甲芬那酸、萘普生、吡罗昔康。

结论

口腔健康专业人员需要了解瑞德西韦与牙科常用药物之间可能发生的潜在药物相互作用,以防止可能危及 COVID-19 患者生命的不良反应,这在临床上是必要的。

相似文献

1
Remdesivir-COVID-19: drug interactions in dentistry.瑞德西韦-COVID-19:牙科中的药物相互作用。
Eur Rev Med Pharmacol Sci. 2020 Sep;24(18):9739-9743. doi: 10.26355/eurrev_202009_23065.
2
Remdesivir and Potential Interactions With Psychotropic Medications: A COVID-19 Perspective.瑞德西韦及其与精神药物的潜在相互作用:从COVID-19角度看
Prim Care Companion CNS Disord. 2020 May 28;22(3):20com02664. doi: 10.4088/PCC.20com02664.
3
Audio Interview: New Data on Remdesivir in Covid-19.音频访谈:瑞德西韦治疗新冠病毒病的新数据
N Engl J Med. 2020 May 28;382(22):e94. doi: 10.1056/NEJMe2019975.
4
Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019.瑞德西韦治疗 2019 年冠状病毒引起的肝脏疾病。
Clin Gastroenterol Hepatol. 2020 Nov;18(12):2835-2836. doi: 10.1016/j.cgh.2020.07.050. Epub 2020 Jul 25.
5
Have we found the panacea to COVID-19 with remdesivir, an old but newly packaged drug?我们用瑞德西韦(一种老药新包装)找到了治疗新冠病毒肺炎的万灵药了吗?
J R Coll Physicians Edinb. 2020 Jun;50(2):159-161. doi: 10.4997/JRCPE.2020.217.
6
Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit.瑞德西韦治疗 COVID-19:肺部和静脉联合给药可能提供额外益处。
AAPS J. 2020 May 26;22(4):77. doi: 10.1208/s12248-020-00459-8.
7
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.瑞德西韦治疗成人重症 COVID-19 的随机、双盲、安慰剂对照、多中心临床试验。
Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29.
8
Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment.瑞德西韦治疗 COVID-19:系统的获益-风险评估。
Drug Saf. 2020 Jul;43(7):645-656. doi: 10.1007/s40264-020-00952-1.
9
Compassionate Use of Remdesivir for Patients with Severe Covid-19.瑞德西韦在治疗重症 COVID-19 患者中的同情使用。
N Engl J Med. 2020 Jun 11;382(24):2327-2336. doi: 10.1056/NEJMoa2007016. Epub 2020 Apr 10.
10
Antiviral treatment for COVID-19: the evidence supporting remdesivir.针对 COVID-19 的抗病毒治疗:瑞德西韦的证据支持。
Clin Med (Lond). 2020 Nov;20(6):e215-e217. doi: 10.7861/clinmed.2020-0524. Epub 2020 Aug 30.

引用本文的文献

1
Unveiling Drug-Drug Interactions in Dental Patients: A Retrospective Real-World Study.揭示牙科患者中的药物相互作用:一项回顾性真实世界研究。
Dent J (Basel). 2025 Jun 9;13(6):255. doi: 10.3390/dj13060255.
2
Factors Modulating COVID-19: A Mechanistic Understanding Based on the Adverse Outcome Pathway Framework.调节2019冠状病毒病的因素:基于不良结局途径框架的机制理解
J Clin Med. 2022 Jul 31;11(15):4464. doi: 10.3390/jcm11154464.